The announcement released by the pharmaceutical multinational is a shocking one, in fact there would be 6,200 redundancies in the world. In the Monza office, the 1,000 employees remain worried
Monza, 24 November 2010 – One hundred and fifty fewer seats at the Roche di Monza. This is the territorial consequence of the 6,200 redundancy plan that the pharmaceutical multinational has announced worldwide. «Roche wants to make 150 cuts in Italy. Since no interventions are planned on the Segrate site, these redundancies will only concern Monza where 1,260 people currently work», explains Maurizio Paltan of Filcem-Cgil.
"We are not yet went into detail, but most of the cuts, around 70%, will concern scientific representatives who depend on Monza, but are scattered throughout Italy. But several redundancies will also affect the employees of the Monza site", adds Paltan.
In the past the operation which was to lead to the sale of a branch of the company (with the simultaneous transfer of 75 scientific representatives and marketing personnel on some "mature" products) to the multinational Quintiles whose headquarters Italian is in Cassina de' Pecchi. "We reject the plan and the cuts and in the next few days we will decide which initiatives to fight to implement", says Platan.
An operation necessary "in the face of growing pressure on costs and obstacles for the approval of new drugs and the definition of prices", explains a note from Roche confirming the 150 redundancies: "Roche will manage this delicate and difficult moment in a socially responsible way".
Fabio Lombardi 
